comparemela.com

Latest Breaking News On - Sponsored leveli american depositary receipt - Page 18 : comparemela.com

Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting

Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) reports that the U.S. Food and Drug Administration (FDA) has today announced

France generalUnited statesUnited kingdomAnna gibbinsIpsen euronextRachel reiffMetabolic drugs advisory committeeGlobal head of franchise communicationsUs head of franchise communicationsDrug administrationRegulatory newsFibrodysplasia ossificans progressivaRare diseaseWith specialty careSponsored leveli american depositary receiptFrench autorit

Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology

Press release content from Business Wire. The AP news staff was not involved in its creation.

France generalUnited statesUnited kingdomDavid loewElizabeth kalinaIpsen euronextCancer research united kingdomDrug administrationEpizyme incLymphoma research foundationCommunications patient advocacyAccelerated approvalChief executive officerPrescribing informationRare diseaseWith specialty care

Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc to 11 August 2022

Extension allows for satisfaction of the HSR Condition as outlined in the Merger Agreement Epizyme stockholders are encouraged to tender their shares to the offer today Regulatory News: Ipsen

France generalUnited kingdomUnited statesIpsen sa euronextIoana piscociuComputershare trust companyExchange commissionIpsen biopharmaceuticals incHibernia merger sub incEpizyme incHibernia merger subHart scott rodino antitrust improvements actTrust companyTender offer statementIpsen biopharmaceuticalsIpsen pharma

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer

Press release content from Business Wire. The AP news staff was not involved in its creation.

France generalUnited statesT ai peiUnited kingdomHoward mayerIpsen euronextEuropean organization for researchHead of researchGlobal head of franchise communications oncologyExecutive vice presidentEuropean organizationCancer qualityLife questionnaire lung cancerReproductive potentialRare diseaseWith specialty care

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

At the primary analysis, the trial did not meet its primary endpoint of overall survival (OS) The safety profile was consistent with previously reported studies of Onivyde (irinotecan liposomal

France generalUnited statesT ai peiUnited kingdomHoward mayerIpsen euronextEuropean organization for researchHead of researchGlobal head of franchise communications oncologyExecutive vice presidentEuropean organizationCancer qualityLife questionnaire lung cancerReproductive potentialRare diseaseWith specialty care

vimarsana © 2020. All Rights Reserved.